메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Jeon Sang-Won (IMDpharm Inc) Park Jin-Hyun (College of Pharmacy Ajou University) Kim Joo-Eun (Department of Biopharmaceutical Chemistry Kookmin University) Park Young-Joon (College of Pharmacy Ajou University)
저널정보
한국약제학회 Journal of Pharmaceutical Investigation Journal of Pharmaceutical Investigation 제53권 제3호
발행연도
2023.5
수록면
407 - 416 (10page)
DOI
10.1007/s40005-023-00611-4

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose Bepotastine besilate, a second-generation antihistamine commonly prescribed to treat allergic rhinitis and urticarial/ pruritus, has a short half-life (t1/2) and is currently available as an immediate-release tablet, administered twice daily. The development of a sustained-release bepotastine formulation remains limited. Methods An experimental method was used to develop a sustained-release bepotastine tablet that can be taken once daily. The formulated sustained-release bepotastine tablet was biologically equivalent to the commercially available Talion® taken twice daily. Considering the target formulation characteristics, the in vitro dissolution rates at 1, 3, and 10 h were predicted as critical quality attributes, taking into account the dissolution and bioequivalence profile of Talion®. Results Factors capable of critically impacting the sustained-release pattern were selected by performing a screening study; the X value, which affects the Y value (1, 3, and 10 h dissolution rates), was identified using hydroxypropyl methylcellulose, polyvinyl-alcohol, and citric acid. For the three identified independent variables, a design space was derived using the extreme vertices design from among the experimental design mixture methods, optimized within the X values of the derived design space. The optimized formulation employed a direct compression process to minimize time and cost. The dissolution rates at 1, 3, and 10 h were 24.9, 47.4, and 88.8%, respectively, exhibiting an appropriate dissolution profile to induce sustainedrelease effects in the human body. Conclusion Bepotastine sustained-release tablet, which can be administered once daily, developed by applying the design of experiment method, was biologically equivalent to the Talion® tablet, which is administered twice daily. Therefore, the developed sustained-release technology using two or more hydrophilic polymers can be applied to various pharmaceuticals in the future as a platform to overcome the technical and commercial limitations of sustained-release agents.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0